Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTL NASDAQ:DMTK NASDAQ:PSNL NASDAQ:RDNT NASDAQ:RNLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$19.02-2.5%$18.01$15.45▼$35.84$552.46M1.1419,897 shs21,372 shsDMTKDermTech$0.19$0.09▼$3.90$3.29M2.481.07 million shs3.66 million shsPSNLPersonalis$6.30-2.6%$5.65$1.62▼$7.79$556.42M1.951.07 million shs124,295 shsRDNTRadNet$57.38+1.4%$57.05$45.00▼$93.65$4.32B1.41681,580 shs186,254 shsRNLXRenalytix$0.21$0.23$0.18▼$2.40$17.18M2.721.45 million shs934,496 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences-0.81%+0.21%+4.00%-7.36%+5.12%DMTKDermTech0.00%0.00%0.00%0.00%+24.88%PSNLPersonalis+1.57%-3.14%+7.65%+98.47%+289.76%RDNTRadNet+2.00%+2.41%+2.13%+6.61%-7.85%RNLXRenalytix0.00%0.00%0.00%0.00%-40.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSTLCastle Biosciences2.2864 of 5 stars3.52.00.00.02.52.50.0DMTKDermTechN/AN/AN/AN/AN/AN/AN/AN/APSNLPersonalis3.4503 of 5 stars2.51.00.04.22.32.50.6RDNTRadNet3.4759 of 5 stars2.82.00.04.61.52.50.0RNLXRenalytixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 3.00Buy$37.0089.74% UpsideDMTKDermTech 0.00N/AN/AN/APSNLPersonalis 3.00Buy$7.6718.50% UpsideRDNTRadNet 3.50Strong Buy$69.6022.99% UpsideRNLXRenalytix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DMTK, RNLX, RDNT, PSNL, and CSTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025RDNTRadNetTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$74.006/13/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$69.006/12/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/15/2025PSNLPersonalisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/7/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.00(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$332.07M1.70$0.98 per share19.98$16.28 per share1.20DMTKDermTech$15.66M0.00N/AN/A$1.67 per share0.00PSNLPersonalis$84.61M6.75N/AN/A$2.87 per share2.25RDNTRadNet$1.87B2.27$3.55 per share15.93$15.31 per share3.70RNLXRenalytix$2.29M7.50N/AN/A($0.10) per share-2.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)DMTKDermTech-$100.89M-$2.70N/AN/AN/A-572.19%-138.79%-68.96%N/APSNLPersonalis-$81.28M-$1.29N/AN/AN/A-98.10%-48.78%-34.70%8/6/2025 (Estimated)RDNTRadNet$2.79M-$0.43N/A106.77N/A-1.73%1.41%0.48%8/6/2025 (Estimated)RNLXRenalytix-$33.46M-$0.39N/A∞N/A-1,461.60%N/A-281.40%N/ALatest DMTK, RNLX, RDNT, PSNL, and CSTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025PSNLPersonalis-$0.25N/AN/AN/A$20.12 millionN/A8/6/2025Q2 2025RDNTRadNet$0.17N/AN/AN/A$488.06 millionN/A8/4/2025Q2 2025CSTLCastle Biosciences-$0.44N/AN/AN/A$71.53 millionN/A5/6/2025Q1 2025PSNLPersonalis-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/ADMTKDermTechN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ARNLXRenalytixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.029.379.19DMTKDermTechN/A3.533.46PSNLPersonalisN/A6.916.74RDNTRadNet0.872.012.01RNLXRenalytixN/A0.530.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%DMTKDermTech20.45%PSNLPersonalis61.91%RDNTRadNet77.90%RNLXRenalytix9.92%Insider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences7.20%DMTKDermTech5.10%PSNLPersonalis3.80%RDNTRadNet5.60%RNLXRenalytix18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54028.87 million26.79 millionOptionableDMTKDermTech26034.96 million33.18 millionOptionablePSNLPersonalis40088.32 million84.97 millionOptionableRDNTRadNet11,02175.03 million70.83 millionOptionableRNLXRenalytix10082.96 million63.06 millionOptionableDMTK, RNLX, RDNT, PSNL, and CSTL HeadlinesRecent News About These CompaniesRenalytix shares gain as billable test numbers set new company recordApril 10, 2025 | proactiveinvestors.co.ukRenalytix Adjusts Share Capital Amid Fundraising ShortfallNovember 6, 2024 | markets.businessinsider.comRenalytix PLC (RNLX) Stock: Unveiling Its Hidden StrengthsOctober 2, 2024 | bovnews.comBRenalytix PLC (RNLX) Stock: Surpassing Expectations in the Market?September 11, 2024 | bovnews.comBWhat Factors Have Led to Renalytix PLC (RNLX) Stock Trading -90.00% Below Its 52-Week High?September 2, 2024 | bovnews.comBThe Renalytix Plc ADR (RNLX) Stock expansion path aheadJuly 23, 2024 | bovnews.comBRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond USJuly 11, 2024 | globenewswire.comRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting DeterminationJune 27, 2024 | globenewswire.comMedicare Issues Final Coverage Determination for kidneyintelX.dkdJune 14, 2024 | globenewswire.comWhat do you think? Take A Moment To Read: Renalytix Plc ADR (RNLX) StockMay 27, 2024 | bovnews.comBIs Renalytix Plc ADR (RNLX) Stock Paving the Way for Earnings?May 16, 2024 | bovnews.comBRNLX Stock Earnings: Renalytix Misses EPS, Misses Revenue for Q3 2024May 15, 2024 | investorplace.comRenalytix AI GAAP EPS of -$0.08 beats by $0.01, revenue of $0.54M misses by $0.56MMay 15, 2024 | msn.comRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2024May 15, 2024 | globenewswire.comRenalytix AI is about to announce its earnings — here's what Wall Street expectsMay 15, 2024 | markets.businessinsider.comRenalytix AI earnings: here's what Wall Street expectsMay 14, 2024 | markets.businessinsider.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15May 9, 2024 | finance.yahoo.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15May 9, 2024 | globenewswire.comRenalytix Plc (RNLX) Stock Price, News, Quote & History - Yahoo FinanceApril 28, 2024 | finance.yahoo.comRenalytix files to sell 19.99M ordinary shares for holdersApril 17, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMTK, RNLX, RDNT, PSNL, and CSTL Company DescriptionsCastle Biosciences NASDAQ:CSTL$19.02 -0.49 (-2.49%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.DermTech NASDAQ:DMTKDermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.Personalis NASDAQ:PSNL$6.30 -0.17 (-2.63%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.RadNet NASDAQ:RDNT$57.38 +0.79 (+1.39%) As of 10:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Renalytix NASDAQ:RNLXRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVDA Greenlight: China H20 Sales Spark 50% Rally Potential New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning Tilray Shares Blazing: What's Behind the 55% Rally This Month? Will Dollar Tree Break Out After a New $2.5 Billion Buyback? The Reason Analysts Are Bullish on Bloom Energy Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
